Heart Failure

ICYMI: HFpEF an Emerging Opportunity in Structural Heart

 ICYMI: HFpEF an Emerging Opportunity in Structural Heart

Start-ups are developing transcatheter treatments for a type of heart failure that has been increasing in prevalence: heart failure with preserved ejection fraction. HFpEF is a huge potential device market because it appears to develop from an accumulation of damages that come with aging rather than a specific cause like heart attack or valve dysfunction.

*Special Edition* 'Meet the Innovators' - Billy Cohn, MD, VP, Johnson & Johnson's Medical Devices Companies, Director, CDI @ TMC

*Special Edition* 'Meet the Innovators' - Billy Cohn, MD, VP, Johnson & Johnson's Medical Devices Companies, Director, CDI @ TMC

“Billy Cohn, MD: Making Medtech Makers at Johnson & Johnson’s CDI @TMC” In this candid video interview onsite at the Center for Device Innovation in Houston, TX, Billy Cohn, MD, VP of Johnson & Johnson’s Medical Device Companies and Director, CDI @ TMC reflects on his extensive device patent journey and shares the keys to overcoming the never-ending challenges that plague device innovation.

'Meet the Innovators' - Arnaud Mascarell, Co-founder & CEO, FineHeart SA

'Meet the Innovators' - Arnaud Mascarell, Co-founder & CEO, FineHeart SA

“FineHeart: A Disruptively Simple Solution for Advanced Heart Failure” France-based FineHeart SA aims to make an impact on the second leading cause of death in the US and in Europe: heart failure (HF) with its first patented product ICOMS. The ICOMS is a hybrid system composed of a pulsatile smart pump, an electrical synchronization module, a control board, and an energy module powered by a TET system. In this interview, CEO Arnaud Mascarell talks about his early inspiration, his experiences in co-founding the company and what’s next for FineHeart.